Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial

By afschroeder • February 11, 2026

Bishop CW, Ashfaq A, Choe J, Strugnell SA, Johnson LL, Norris KC, Sprague SM. Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial. Am J Nephrol. 2026;57(1):109-119. doi: 10.1159/000546615. Epub 2025 Jun 4. PMID: 40466630; PMCID: PMC12193742.

Tags: end-stage kidney disease, Extended-release calcifediol, General Internal Medicine, Hemodialysis, Parathyroid hormone, Publications, secondary hyperparathyroidism

Related Posts

Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis

Kishan AU, Sun Y, Parker CC, Sargos P, Sydes MR, Chabaud S, Brihoum M, Kalbasi TR, Steinberg ML, Valle LF, Taparra K, Shoag JE, Garcia[...]

Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study

Nguyen XT, Li Y, Czernichow S, Rassy N, Houghton SC, Lu B, Ho YL, Charest BR, Wang DD, Gagnon DR, Gaziano JM, Willett WC, Wilson[...]

Discontinuation of statins by patient and physician sex: An observational study

Watanabe A, Miyamoto Y, Ueyama HA, Gotanda H, Slipczuk L, Inoue K, Secemsky E, Laham R, Bhatt DL, Tsugawa Y, Kuno T. Discontinuation of statins[...]